vs
Amphastar Pharmaceuticals, Inc.（AMPH）与REPUBLIC BANCORP INC（RBCAA）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是REPUBLIC BANCORP INC的1.9倍（$183.1M vs $94.3M），REPUBLIC BANCORP INC净利率更高（24.2% vs 13.3%，领先10.9%），REPUBLIC BANCORP INC同比增速更快（5.3% vs -1.8%），REPUBLIC BANCORP INC自由现金流更多（$161.1M vs $24.6M），过去两年Amphastar Pharmaceuticals, Inc.的营收复合增速更高（3.2% vs -11.5%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
肯塔基州共和银行是美国的一家区域性银行控股企业，提供零售及商业银行全品类服务，涵盖个人存贷款、企业融资、按揭产品及财富管理解决方案，主要服务肯塔基州及周边州的个人消费者和中小企业客户。
AMPH vs RBCAA — 直观对比
营收规模更大
AMPH
是对方的1.9倍
$94.3M
营收增速更快
RBCAA
高出7.1%
-1.8%
净利率更高
RBCAA
高出10.9%
13.3%
自由现金流更多
RBCAA
多$136.5M
$24.6M
两年增速更快
AMPH
近两年复合增速
-11.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $94.3M |
| 净利润 | $24.4M | $22.8M |
| 毛利率 | 46.8% | — |
| 营业利润率 | 19.4% | 29.3% |
| 净利率 | 13.3% | 24.2% |
| 营收同比 | -1.8% | 5.3% |
| 净利润同比 | -35.7% | 20.0% |
| 每股收益（稀释后） | $0.51 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHRBCAA
| Q4 25 | $183.1M | $94.3M | ||
| Q3 25 | $191.8M | $93.5M | ||
| Q2 25 | $174.4M | $93.8M | ||
| Q1 25 | $170.5M | $135.8M | ||
| Q4 24 | $186.5M | $89.5M | ||
| Q3 24 | $191.2M | $88.1M | ||
| Q2 24 | $182.4M | $86.9M | ||
| Q1 24 | $171.8M | $120.3M |
净利润AMPHRBCAA
| Q4 25 | $24.4M | $22.8M | ||
| Q3 25 | $17.4M | $29.7M | ||
| Q2 25 | $31.0M | $31.5M | ||
| Q1 25 | $25.3M | $47.3M | ||
| Q4 24 | $38.0M | $19.0M | ||
| Q3 24 | $40.4M | $26.5M | ||
| Q2 24 | $37.9M | $25.2M | ||
| Q1 24 | $43.2M | $30.6M |
毛利率AMPHRBCAA
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
营业利润率AMPHRBCAA
| Q4 25 | 19.4% | 29.3% | ||
| Q3 25 | 13.2% | 40.4% | ||
| Q2 25 | 24.2% | 43.0% | ||
| Q1 25 | 21.9% | 44.1% | ||
| Q4 24 | 24.2% | 25.8% | ||
| Q3 24 | 29.8% | 38.4% | ||
| Q2 24 | 30.3% | 37.0% | ||
| Q1 24 | 27.9% | 32.2% |
净利率AMPHRBCAA
| Q4 25 | 13.3% | 24.2% | ||
| Q3 25 | 9.0% | 31.8% | ||
| Q2 25 | 17.8% | 33.5% | ||
| Q1 25 | 14.8% | 34.8% | ||
| Q4 24 | 20.4% | 21.2% | ||
| Q3 24 | 21.1% | 30.1% | ||
| Q2 24 | 20.8% | 29.0% | ||
| Q1 24 | 25.1% | 25.4% |
每股收益（稀释后）AMPHRBCAA
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $0.64 | — | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | — | ||
| Q2 24 | $0.73 | — | ||
| Q1 24 | $0.81 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $220.0M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $1.1B |
| 总资产 | $1.6B | $7.0B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHRBCAA
| Q4 25 | $282.8M | $220.0M | ||
| Q3 25 | $276.2M | $484.2M | ||
| Q2 25 | $231.8M | $484.8M | ||
| Q1 25 | $236.9M | $793.0M | ||
| Q4 24 | $221.6M | $432.2M | ||
| Q3 24 | $250.5M | $530.9M | ||
| Q2 24 | $217.8M | $400.1M | ||
| Q1 24 | $289.6M | $546.4M |
总债务AMPHRBCAA
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHRBCAA
| Q4 25 | $788.8M | $1.1B | ||
| Q3 25 | $776.7M | $1.1B | ||
| Q2 25 | $757.5M | $1.1B | ||
| Q1 25 | $751.3M | $1.0B | ||
| Q4 24 | $732.3M | $992.0M | ||
| Q3 24 | $727.7M | $979.7M | ||
| Q2 24 | $713.3M | $955.4M | ||
| Q1 24 | $672.4M | $935.6M |
总资产AMPHRBCAA
| Q4 25 | $1.6B | $7.0B | ||
| Q3 25 | $1.7B | $7.0B | ||
| Q2 25 | $1.6B | $7.0B | ||
| Q1 25 | $1.6B | $7.1B | ||
| Q4 24 | $1.6B | $6.8B | ||
| Q3 24 | $1.5B | $6.7B | ||
| Q2 24 | $1.5B | $6.6B | ||
| Q1 24 | $1.6B | $6.9B |
负债/权益比AMPHRBCAA
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $168.2M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $161.1M |
| 自由现金流率自由现金流/营收 | 13.4% | 170.9% |
| 资本支出强度资本支出/营收 | 4.5% | 7.5% |
| 现金转化率经营现金流/净利润 | 1.35× | 7.37× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $288.6M |
8季度趋势，按日历期对齐
经营现金流AMPHRBCAA
| Q4 25 | $32.9M | $168.2M | ||
| Q3 25 | $52.6M | $33.3M | ||
| Q2 25 | $35.6M | $8.4M | ||
| Q1 25 | $35.1M | $93.2M | ||
| Q4 24 | $29.0M | $149.0M | ||
| Q3 24 | $60.0M | $51.3M | ||
| Q2 24 | $69.1M | $4.0M | ||
| Q1 24 | $55.3M | $71.2M |
自由现金流AMPHRBCAA
| Q4 25 | $24.6M | $161.1M | ||
| Q3 25 | $47.2M | $30.8M | ||
| Q2 25 | $25.0M | $5.2M | ||
| Q1 25 | $24.4M | $91.6M | ||
| Q4 24 | $16.6M | $143.2M | ||
| Q3 24 | $46.2M | $49.8M | ||
| Q2 24 | $63.1M | $2.7M | ||
| Q1 24 | $46.5M | $69.1M |
自由现金流率AMPHRBCAA
| Q4 25 | 13.4% | 170.9% | ||
| Q3 25 | 24.6% | 32.9% | ||
| Q2 25 | 14.3% | 5.5% | ||
| Q1 25 | 14.3% | 67.4% | ||
| Q4 24 | 8.9% | 160.0% | ||
| Q3 24 | 24.1% | 56.5% | ||
| Q2 24 | 34.6% | 3.1% | ||
| Q1 24 | 27.1% | 57.5% |
资本支出强度AMPHRBCAA
| Q4 25 | 4.5% | 7.5% | ||
| Q3 25 | 2.8% | 2.6% | ||
| Q2 25 | 6.1% | 3.5% | ||
| Q1 25 | 6.3% | 1.2% | ||
| Q4 24 | 6.7% | 6.5% | ||
| Q3 24 | 7.2% | 1.7% | ||
| Q2 24 | 3.3% | 1.5% | ||
| Q1 24 | 5.1% | 1.7% |
现金转化率AMPHRBCAA
| Q4 25 | 1.35× | 7.37× | ||
| Q3 25 | 3.03× | 1.12× | ||
| Q2 25 | 1.15× | 0.27× | ||
| Q1 25 | 1.39× | 1.97× | ||
| Q4 24 | 0.76× | 7.84× | ||
| Q3 24 | 1.48× | 1.93× | ||
| Q2 24 | 1.82× | 0.16× | ||
| Q1 24 | 1.28× | 2.33× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
RBCAA
暂无分部数据
